Correction to: Neuropsychopharmacology (2013) 38, 1636–1647; doi:10.1038/npp.2013.60

In this article, the following collaborators of The GESGA Consortium are being added to the byline: Jens Treutlein1, Sven Cichon2,3,4,5, Monika Ridinger6, Manuel Mattheisen2,7,8, Stefan Herms2,3,5, Norbert Wodarz6, Peter Zill9, Wolfgang Maier10, Rainald Mössner10, Wolfgang Gaebel11, Norbert Dahmen12, Norbert Scherbaum13, Christine Schmäl1, Michael Steffens7, Susanne Lucae14, Marcus Ising15, Bertram Müller-Myhsok16, Markus M Nöthen2,3,17, Karl Mann18, and Marcella Rietschel1

1Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Heidelberg, Germany; 2Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany; 3Institute of Human Genetics, University of Bonn, Bonn, Germany; 4Institute of Neuroscience and Medicine (INM-1), Research Center Juelich, Juelich, Germany; 5Division of Medical Genetics, Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Germany; 6Department of Psychiatry, University Medical Center Regensburg, University of Regensburg, Regensburg, Germany; 7Institute for Medical Biometry, Informatics, and Epidemiology, University of Bonn, Bonn, Germany; 8Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA; 9Department of Psychiatry, University of Munich, Munich, Germany; 10Department of Psychiatry, University of Bonn, Bonn, Germany; 11Department of Psychiatry and Psychotherapy, University of Düsseldorf, Düsseldorf, Germany; 12Department of Psychiatry, University of Mainz, Mainz, Germany; 13Addiction Research Group at the Department of Psychiatry and Psychotherapy, LVR Hospital Essen, University of Duisburg-Essen, Essen, Germany; 14Department of Psychiatric Pharmacogenetics, Max-Planck-Institute of Psychiatry, Munich, Germany; 15Department of Molecular Psychology, Max-Planck-Institute of Psychiatry, Munich, Germany; 16Department of Statistical Genetics, Max-Planck-Institute of Psychiatry, Munich, Germany; 17German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; 18Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Heidelberg, Germany.

FUNDING AND DISCLOSURE

MR has received compensation for advisory activities from Lundbeck. NW received funds by Lundbeck and D&A Pharma for taking part in multi-centre randomized trials. He received speaker’s honoraria and travel funds from Janssen-Cilag and Essex Pharma. NS received honoraria as an advisory board member of Sanofi-Aventis and Reckitt-Benckiser. He received lecture honoraria from Janssen, Lundbeck and Reckitt Benckiser.